Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: A review of the H. Lee Moffitt Cancer Center experience

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 5, 2006, Pages 384-390

  Torres Roca, Javier F ^a   Cantor, Alan B ^a   Shukla, Sonia ^a   Montejo, Michael E ^a   Friedland, Jay ^a   Seigne, John D ^b   Heysek, Randy ^a   Pow Sang, Julio ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Brachytherapy monotherapy; Perineural invasion; Prostate cancer

Indexed keywords

IODINE 125;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748189293     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.12.003     Document Type: Article

References (30)

1. Quaranta B.P., Marks L.B., and Anscher M.S. Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Huntingt) 18 (2004) 1289-1302
2. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
3. Critz F.A., Williams W.H., Levinson A.K., et al. Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques. J Urol 164 (2000) 738-741
4. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer 97 (2003) 979-983
5. Lederman G.S., Cavanagh W., Albert P.S., et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 49 (2001) 1297-1303
6. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 57 (2003) 944-952
7. Davis B.J., Haddock M.G., Wilson T.M., et al. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: Is extraprostatic seed placement necessary?. Tech Urol 6 (2000) 70-77
8. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 55 (2000) 382-386
9. Sarosdy M.F. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer 101 (2004) 754-760
10. Speight J.L., Elkin E.P., Pasta D.J., et al. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: Data from CaPSURE. Int J Radiat Oncol Biol Phys 60 (2004) 1066-1075
11. Brandeis J., Pashos C.L., Henning J.M., et al. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 89 (2000) 1792-1799
12. Cox J.D., Grignon D.J., Kaplan R.S., and American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
13. American Joint Committee on Cancer, American Cancer Society, and American College of Surgeons. AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia (PA)
14. Kaplan E.L., and Meier P.L. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. Greenwood M. The natural duration of cancer. Rep Public Health Med Subj (Lond) 33 (1926) 1-26
16. Mantel N. Evaluation of survival data and 2wo new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
17. Merrick G.S., Butler W.M., Galbreath R.W., et al. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J 7 (2001) 404-412
18. Grann A., Gaudin P.B., Raben A., et al. Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy. Radiat Oncol Investig 6 (1998) 170-174
19. Anderson P.R., Hanlon A.L., Patchefsky A., et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 41 (1998) 1087-1092
20. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
21. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
22. Padula G.D., Zelefsky M.J., Venkatraman E.S., et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 439-443
23. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
24. Sharkey J., Cantor A., Solc Z., et al. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep 3 (2002) 250-257
25. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48 (2000) 111-117
26. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
27. Kwok Y., DiBiase S.J., Amin P.P., et al. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 588-594
28. Stokes S.H. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 47 (2000) 129-136
29. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
30. Ragde H., Korb L.J., Elgamal A.A., et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 89 (2000) 135-141